Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Retained Earnings (2016 - 2025)

Kiora Pharmaceuticals (KPRX) has disclosed Retained Earnings for 11 consecutive years, with -$243708.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Retained Earnings fell 224.05% year-over-year to -$243708.0, compared with a TTM value of -$243708.0 through Sep 2025, down 224.05%, and an annual FY2024 reading of -$282159.0, up 99.81% over the prior year.
  • Retained Earnings was -$243708.0 for Q3 2025 at Kiora Pharmaceuticals, up from -$245770.0 in the prior quarter.
  • Across five years, Retained Earnings topped out at $9671.0 in Q1 2021 and bottomed at -$147.0 million in Q4 2023.
  • Average Retained Earnings over 5 years is -$45.4 million, with a median of -$245752.5 recorded in 2024.
  • The sharpest move saw Retained Earnings skyrocketed 100.01% in 2021, then crashed 1286878.65% in 2022.
  • Year by year, Retained Earnings stood at -$120.9 million in 2021, then decreased by 9.17% to -$132.0 million in 2022, then fell by 11.38% to -$147.0 million in 2023, then surged by 99.81% to -$282159.0 in 2024, then rose by 13.63% to -$243708.0 in 2025.
  • Business Quant data shows Retained Earnings for KPRX at -$243708.0 in Q3 2025, -$245770.0 in Q2 2025, and -$145.6 million in Q1 2025.